510(k) Report

510(k) · Cleared

Cleared

Solitaire 4 Revascularization Device

K183022510(k) TraditionalCleared Jan 29, 201989-day reviewClass II21 CFR 882.5600

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Micro Therapeutics, Inc. d/b/a ev3 Neurovascular · POL Neurovascular Mechanical Thrombectomy Device For Acute Ischemic Stroke Treatment

Cleared on Jan 29, 2019 as substantially equivalent to K181186 (Micro Therapeutics, Inc. d/b/a ev3 Neurovascular, 2018) after an 89-day review. Its family tree reaches back 11 generations to 2001. 2 later devices descend from it.

Decided
Jan 29, 2019
Review
89 days
Class
Class II
Product code
POL
Recalls
None
Predicates
1

Its longest line of descent runs back 11 generations to K003410 (2001). 20 ancestors in all. 2 later devices descend from it, 2 citing it directly.

  1. Root · 11 generations backK003410 Concentric Retriever, Model 90030Concentric Medical, Inc. · 2001 · Recalled
  2. 7 generations between
  3. 3 generations backK153071 Solitaire Platinum Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · 2015
  4. 2 generations backK161879 Solitaire Platinum Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · 2016
  5. 1 generation backK181186 Solitare Platinum Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · 2018
  6. This deviceK183022 Solitaire 4 Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · 2019
  7. Descendant · cites it directly · 0 of its ownK203358 Solitaire X Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · 2021
  8. Descendant · cites it directly · 0 of its ownK193576 Solitaire Platinum Revascularization Device, Solitaire X…Micro Therapeutics, Inc. d/b/a ev3 Neurovascular · 2020
Show all 11 generations
  1. Root · 11 generations backK003410 Concentric Retriever, Model 90030Concentric Medical, Inc. · 2001 · Recalled
  2. 10 generations backK030476 Modified Concentric Retriever, Model 90037Concentric Medical, Inc. · 2003 · Recalled
  3. 9 generations backK033736 Merci Retriever, Models 90065, 90066Concentric Medical, Inc. · 2004
  4. 8 generations backK063774 Modification to Merci Retriever, Models X5 and X6Concentric Medical, Inc. · 2007
  5. 7 generations backK090085 Merci Retriever, Models 90050, 90060, 90066, 90070, 90110, 90111…Concentric Medical, Inc. · 2009
  6. 6 generations backK113455 Solitaire FR Revascularization DeviceMicro Therapeutics Dba Ev3 Neurovascular · 2012
  7. 5 generations backK123378 Solitaire 2 Revascularization DeviceMicro Therapeutics Dba Ev3 Neurovascular · 2012
  8. 4 generations backK141491 Solitaire 2 Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · 2014
  9. 3 generations backK153071 Solitaire Platinum Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · 2015
  10. 2 generations backK161879 Solitaire Platinum Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · 2016
  11. 1 generation backK181186 Solitare Platinum Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · 2018
  12. This deviceK183022 Solitaire 4 Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · 2019

Most influential descendants

Showing 2 of 2 · See all
  • K203358Solitaire X Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · 2021 · cites it directly0descendants
  • K193576Solitaire Platinum Revascularization Device, Solitaire X Revascularization Device…Micro Therapeutics, Inc. d/b/a ev3 Neurovascular · 2020 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−11K003410Concentric Retriever, Model 90030Concentric Medical, Inc.20011
−10K030476Modified Concentric Retriever, Model 90037Concentric Medical, Inc.20032
−9K033736Merci Retriever, Models 90065, 90066Concentric Medical, Inc.2004—
−8K063774Modification to Merci Retriever, Models X5 and X6Concentric Medical, Inc.2007—
−7K090085Merci Retriever, Models 90050, 90060, 90066, 90070, 90110, 90111, 90112, 90113Concentric Medical, Inc.2009—
−6K113455Solitaire FR Revascularization DeviceMicro Therapeutics Dba Ev3 Neurovascular2012—
−5K123378Solitaire 2 Revascularization DeviceMicro Therapeutics Dba Ev3 Neurovascular2012—
−4K141491Solitaire 2 Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular2014—
−3K153071Solitaire Platinum Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular2015—
−2K161879Solitaire Platinum Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular2016—
−1K181186Solitare Platinum Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular2018—
0 (this device)K183022Solitaire 4 Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular2019—
+1K203358Solitaire X Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular2021—
+1K193576Solitaire Platinum Revascularization Device, Solitaire X Revascularization…Micro Therapeutics, Inc. d/b/a ev3 Neurovascular2020—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
200610
200730
200820
201620
201710

Descendants by year cleared

Year clearedDevicesWith a Class I recall
202010
202110
FIG. 1 — Lineage of K183022, 2001–2021Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in POL? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new POL device

  1. #1 K222848 pRESET Thrombectomy Devicescore 11.0 · 2 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K181186Solitare Platinum Revascularization Device
Summary page 4
…cation of Class II, 21 CFR 882.5600; 21 CFR 870.1250 Device: Product Code: POL; NRY Predicate Device: Solitaire™ Platinum Revascularization Device (K181186) Device Description: The Solitaire™ 4 Revascularization Device is designed to restore blood flow in patients experiencing ischem…
Micro Therapeutics, Inc. d/b/a ev3 Neurovascular2018—

Also cleared against K181186: 1 other device →

What descends from it? (2)

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K203358Solitaire X Revascularization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular20210
K193576Solitaire Platinum Revascularization Device, Solitaire X Revascularization Device…Micro Therapeutics, Inc. d/b/a ev3 Neurovascular20200

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 18 years and passes through 3 companies; a new generation was cleared every 1.8 years on median.
  • 3 of the 20 ancestors have a recall of any class.
  • Of its descendants, K203358 (Micro Therapeutics, Inc. d/b/a ev3 Neurovascular, 2021) has gone furthest, with 0 descendants of its own.
  • 1 other device also cites its predicate K181186.

How does its category compare?

All POL devices

POL Neurovascular Mechanical Thrombectomy Device For Acute Ischemic Stroke Treatment: FDA decisions, review times, recalls and adverse event reports over 20 years. 2019, this device’s year, is highlighted.

FDA decisions per year · POL

1in 2025

2016: 22018: 32019: 42020: 32021: 22023: 32025: 1
2007high 4 (2019) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · POL

144in 2023

2018: 123 days median2019: 95 days median2020: 57 days median2023: 144 days median
2007high 144 (2023) · low 57 (2020)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · POL

1in 2020

2020: 1, 1 Class I
2007high 1 (2020) · low 0 (2007)2026

Class I (1 since 2007) Class II/III not classified

Adverse event reports per year · POL

16in 2025

2019: 12020: 62021: 212022: 102023: 232024: 112025: 16
2007high 23 (2023) · low 0 (2007)2025

MAUDE reports naming product code POL, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20162—00
20170—00
2018312300
201949501
20203571 (1)6
20212—021
20220—010
20233144023
20240—011
20251—016
20260—0—

What is it indicated for?

1. The Solitaire™ Revascularization Device is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA). Endovascular therapy with the device should be started within 6 hours of…

Read the full statement (115 words)

1. The Solitaire™ Revascularization Device is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA). Endovascular therapy with the device should be started within 6 hours of symptom onset.

2. The Solitaire™ Revascularization Device is indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for IV t-PA or who fail IV t-PA therapy are candidates for treatment.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K183022: Solitaire 4 Revascularization Device.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K183022

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026